Australian Gonococcal Surveillance Programme, 1 April to 30 June 2024

Authors

  • Monica M Lahra The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW, 2031, Australia; The School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, 2052, Australia
  • Sebastiaan van Hal Molecular Microbiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
  • Sonya Natasha Hutabarat Department of Microbiology, NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW 2031, Australia
  • Tiffany R Hogan The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW, 2031, Australia

DOI:

https://doi.org/10.33321/cdi.2025.49.002

Keywords:

antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeae

Abstract

The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 April to 30 June 2024.

Downloads

Download data is not yet available.

References

Northern Territory Government Department of Health (NT Health) Centre for Disease Control. Penicillinase-producing Neisseria gonorrhoeae (PPNG) and treatment recommendations for gonorrhoea. Darwin: NT Health; 11 March 2024. [Accessed on 11 July 2024.] Available from: https://health.nt.gov.au/__data/assets/pdf_file/0008/1356146/health-alert-ppng-240311.pdf.

World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.

Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A et al. Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill. 2022;27(46):2200803. doi: https://doi.org/10.2807%2F1560-7917.ES.2022.27.46.2200803.

van Hal SJ, Sherry N, Coombs G, Mowlaboccus, S, Whiley DM, Lahra MM. Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone. Lancet Infect Dis. 2024;24(9):e547–8. doi: https://doi.org/10.1016/S1473-3099(24)00486-9.

Lahra MM, Van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report, 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.45.

van Hal SJ, Whiley DM, Le T, Ray S, Kundu RL, Kerr E et al. Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. J Antimicrob Chemother. 2023;78(9):2203–2208. doi: https://doi.org/10.1093/jac/dkad221.

Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364. doi: https://doi.org/10.1186/s12879-015-1029-2.

Ong JJ, Bourne C, Dean JA, Ryder N, Cornelisse VJ, Murray S et al. Australian sexually transmitted infection (STI) management guidelines for use in primary care, 2022 update. Sex Health. 2023;20(1):1–8. doi: https://doi.org/10.1071/SH22134.

Downloads

Published

22/01/25

How to Cite

Lahra, Monica M, Sebastiaan van Hal, Sonya Natasha Hutabarat, and Tiffany R Hogan. 2025. “Australian Gonococcal Surveillance Programme, 1 April to 30 June 2024”. Communicable Diseases Intelligence 49 (January). https://doi.org/10.33321/cdi.2025.49.002.

Issue

Vol. 49 (2025)

Section

Quarterly report

Categories

License

Copyright (c) 2025 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 12 > >>